Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.40M | $1.40M | $1.73M | $361K | $144K | $34.0K | $3.15M | $56.0K | $130K |
| Revenue growth | — | -0.6% | 23.8% | -79.1% | -60.1% | -76.4% | 9173.5% | -98.2% | 132.1% |
| Gross profit | $1.24M | $1.03M | $1.48M | $335K | $125K | $21.0K | $102K | — | — |
| Gross margin | 88.0% | 73.9% | 85.9% | 92.8% | 86.8% | 61.8% | 3.2% | — | — |
| Operating income | -$6.66M | -$11.2M | -$12.6M | -$10.1M | -$7.93M | -$6.97M | -$3.13M | -$17.0M | -$24.0M |
| Operating margin | -474.6% | -805.5% | -726.8% | -2797.8% | -5509.0% | -20514.7% | -99.2% | -30442.9% | -18478.5% |
| Net income | -$6.58M | -$7.50M | -$12.2M | $2.00M | -$8.68M | -$10.5M | $5.27M | -$11.1M | -$19.2M |
| Net margin | -468.7% | -537.4% | -703.4% | 554.0% | -6024.3% | -30770.6% | 167.1% | -19894.6% | -14755.4% |
| EPS (diluted) | -$0.21 | -$0.21 | -$0.33 | -$0.29 | -$0.23 | -$9.70 | $0.73 | -$1.51 | -$1.91 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.29M | -$8.00M | -$10.2M | -$7.82M | -$7.86M | -$5.94M | -$2.48M | -$17.1M | -$18.0M |
| Capital expenditures | $1.00K | $21.0K | $641K | $20.0K | — | — | $504K | $22.0K | $59.0K |
| Free cash flow | -$6.29M | -$8.02M | -$10.8M | -$7.84M | — | — | -$2.98M | -$17.2M | -$18.0M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.38M | $6.71M | $2.35M | $527K | $584K | $645K | $7.62M | $3.67M | $3.06M |
| Total assets | $9.63M | $10.7M | $7.44M | $3.92M | $3.15M | $3.24M | $8.97M | $6.72M | $6.95M |
| Total liabilities | $1.31M | $2.44M | $4.83M | $9.32M | $15.0M | $20.6M | $4.86M | $6.22M | $6.99M |
| Long-term debt | — | — | — | — | $13.2M | $18.1M | — | — | — |
| Shareholders' equity | $7.28M | $7.45M | $2.22M | -$5.12M | -$11.8M | -$17.2M | -$32.3M | $641K | -$37.0K |
| Retained earnings | -$66.6M | -$74.1M | -$86.2M | -$97.1M | -$106M | -$116M | -$33.2M | -$44.3M | -$63.5M |
| Shares (wtd avg diluted) | 33.8M | 35.8M | 37.6M | 37.7M | 37.9M | 1.08B | 7.35M | 7.36M | 10.2M |
Every figure is extracted from Serina Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.